INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY), the global pharmaceutical firm, has announced a substantial expansion of its shareholder return program. The board of directors... INDIANAPOLIS ...

The investment will benefit millions of patients worldwide, boosting the production of the company's medicines, including those for diabetes and obesity INDIANAPOLIS, Dec. 5,... ByInvesting.com • 06 ...

Last week, Eli Lilly said it would cut the monthly price of its starter dose of Zepbound to $349. The U.S. drugmaker also is making larger doses available for $499 through its self-pay program.

For February’s edition, we highlight CFO takes from Palantir, MicroStrategy, Eli Lilly, Wynn Resorts, Chemours, Walmart, Krispy Kreme, Beyond Meat, Anheuser-Busch InBev and Lemonade. 1. Palantir ...

Eli Lilly said Wednesday it will invest $27 billion to build four new manufacturing plants in the United States as the pharmaceutical giant grapples with the threat of drug import duties from the ...

Eli Lilly plans to invest at least $27 billion to build four new pharmaceutical manufacturing sites in the U.S. The drugmaker, which had committed to $23 billion in domestic investments from 2020 ...

Eli Lilly and Co. Wednesday announced plans to build four pharmaceutical manufacturing sites in the United States, significantly boosting domestic medicine production and adding around 13,000 ...

Eli Lilly on Wednesday said it will invest at least $27 billion to build four new manufacturing sites in the U.S., as demand for its blockbuster weight loss and diabetes injections soars and the ...

Drugmaker Eli Lilly plans to invest up to $27 billion to build four new pharmaceutical manufacturing sites in the U.S., the company announced Wednesday, a move that comes as President Trump is ...

Drugmaker Eli Lilly plans to build four new manufacturing plants in the U.S., a $27 billion investment that the company expects will create 3,000 high-skilled jobs and employ 10,000 construction ...